UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Journal of clinical oncology, 2016-02, Vol.34 (4), p.329-336

2016

Volltextzugriff (PDF)

Targeting MCL-1 in hematologic malignancies: Rationale and progress

Blood reviews, 2020-11, Vol.44, p.100672-100672, Article 100672

2020

Volltextzugriff (PDF)

The present and future of measurable residual disease testing in acute myeloid leukemia

Haematologica (Roma), 2022-12, Vol.107 (12), p.2810-2822

2022

Volltextzugriff (PDF)

The past and future of CD33 as therapeutic target in acute myeloid leukemia

Blood reviews, 2014-07, Vol.28 (4), p.143-153

2014

Volltextzugriff (PDF)

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

Blood, 2013-08, Vol.122 (7), p.1316-1324

2013

Volltextzugriff (PDF)

Evaluating measurable residual disease in acute myeloid leukemia

Blood advances, 2018-06, Vol.2 (11), p.1356-1366

2018

Volltextzugriff (PDF)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

Haematologica (Roma), 2017-05, Vol.102 (5), p.865-873

2017

Volltextzugriff (PDF)

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Blood, 2013-09, Vol.122 (10), p.1813-1821

2013

Volltextzugriff (PDF)

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

Journal of clinical oncology, 2017-08, Vol.35 (23), p.2674-2682

2017

Volltextzugriff (PDF)

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

Blood, 2022-03, Vol.139 (11), p.1694-1706

2022

Volltextzugriff (PDF)

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

Cancer, 2016-06, Vol.122 (12), p.1871-1879

2016

Volltextzugriff (PDF)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia

Haematologica (Roma), 2023-02, Vol.108 (2), p.420-432

2023

Volltextzugriff (PDF)

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Clinical cancer research, 2016-12, Vol.22 (23), p.5829-5838

2016

Volltextzugriff (PDF)

Perspective on measurable residual disease testing in acute myeloid leukemia

Leukemia, 2024-01, Vol.38 (1), p.10-13

Walter, Roland B

2024

Volltextzugriff (PDF)

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Haematologica (Roma), 2023-01, Vol.108 (1), p.273-277

2023

Volltextzugriff (PDF)

Investigational CD33-targeted therapeutics for acute myeloid leukemia

Expert opinion on investigational drugs, 2018-04, Vol.27 (4), p.339-348

Walter, Roland B

2018

Volltextzugriff (PDF)

Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)

Cancers, 2020-12, Vol.12 (12), p.3617

2020

Volltextzugriff (PDF)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia

Haematologica (Roma), 2022-11, Vol.107 (11), p.2752-2755

2022

Volltextzugriff (PDF)

Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms

Leukemia, 2023-02, Vol.37 (2), p.298-307

2023

Volltextzugriff (PDF)

Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1766-1771

2010

Volltextzugriff (PDF)

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

PloS one, 2015-08, Vol.10 (8), p.e0135945-e0135945

2015

Volltextzugriff (PDF)

Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents

Leukemia & lymphoma, 2023-04, Vol.64 (5), p.990-996

2023

Volltextzugriff (PDF)

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Blood, 2013-03, Vol.121 (13), p.2424-2431

2013

Volltextzugriff (PDF)

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

Haematologica (Roma), 2019-02, Vol.104 (2), p.e59-e62

2019

Volltextzugriff (PDF)

1 – 25 von 676

Suche als RSS-Feed

Aktive Filter

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(584)
Mit Volltextzugriff
(549)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(317)
Life Sciences & Biomedicine
(292)
Humans
(228)
Hematology
(168)
Oncology
(120)
Acute Myeloid Leukemia
(106)
Adult
(89)
Male
(87)
Female
(86)
Leukemia, Myeloid, Acute - Drug Therapy
(67)
Leukemia
(63)
Middle Aged
(59)
Aged
(56)
Leukemia, Myeloid, Acute - Therapy
(43)
Treatment Outcome
(40)
Prognosis
(39)
Leukemia, Myeloid, Acute - Diagnosis
(38)
Leukemia, Myeloid, Acute - Mortality
(38)
Animals
(36)
Chemotherapy
(35)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(431)
Single Journals
(308)
MEDLINE
(240)
Journals@Ovid
(179)
Ingenta
(115)
IngentaConnect Journals
(65)
Elsevier ScienceDirect Journals Complete
(59)
Wiley-Blackwell subscription journals
(57)
Nexis Uni
(55)
Nature
(54)
Taylor & Francis
(46)
Wiley Online Library
(45)
Taylor & Francis Journals
(43)
Taylor & Francis E-Journals
(39)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(34)
Ebook Central Perpetual and DDA
(34)
eBooks on EBSCOhost
(30)
SpringerLink
(28)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(18)
JSTOR
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Targeting MCL-1 in hematologic malignancies: Rationale and progress

The present and future of measurable residual disease testing in acute myeloid leukemia

The past and future of CD33 as therapeutic target in acute myeloid leukemia

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

Evaluating measurable residual disease in acute myeloid leukemia

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Perspective on measurable residual disease testing in acute myeloid leukemia

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Investigational CD33-targeted therapeutics for acute myeloid leukemia

Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia

Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms

Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

Aktive Filter

Suchergebnisse filtern